Sugi Predict

Sugi Predict / Compounds / SCHEMBL273405

SCHEMBL273405

SCHEMBL273405

O=[N+]([O-])c1ccc(Cl)c(Cl)c1CO

nearest known ligand 0.60

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ TDP1 Q9NUW8 1/20 0.60
▸ TSHR P16473 2/20 0.44
▸ MAPK1 P28482 1/20 0.44
▸ VCAM1 P19320 9/20 0.43
▸ ALDH1A1 P00352 2/20 0.39
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ MMP1 P03956 1/20 0.39
▸ MMP2 P08253 1/20 0.39
▸ MMP9 P14780 1/20 0.39
▸ MMP8 P22894 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ GPR35 Q9HC97 2/20 0.39
▸ FBP1 P09467 1/20 0.39
▸ USP7 Q93009 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6646572 0.85 TDP1 (0.60) TDP1TSHRMAPK1VCAM1ALDH1A1
SCHEMBL278504 0.83 TDP1 (0.62) TDP1TSHRMAPK1VCAM1ALDH1A1
SCHEMBL31170851 0.82 TDP1 (0.43) TDP1TSHRMAPK1VCAM1ALDH1A1
SCHEMBL14160013 0.82 TDP1 (0.43) TDP1TSHRMAPK1VCAM1ALDH1A1
SCHEMBL278628 0.81 TDP1 (0.60) TDP1TSHRMAPK1VCAM1ALDH1A1
SCHEMBL273093 0.81 TDP1 (0.60) TDP1TSHRMAPK1VCAM1ALDH1A1
SCHEMBL278621 0.81 TDP1 (0.60) TDP1TSHRMAPK1VCAM1ALDH1A1
Hydrochloric Acid SCHEMBL1197124 0.80 TDP1 (0.58) TDP1TSHRMAPK1VCAM1ALDH1A1
SCHEMBL2474011 0.80 TDP1 (0.53) TDP1TSHRMAPK1VCAM1ALDH1A1
SCHEMBL5681342 0.78 ALDH1A1 (0.51) TDP1TSHRMAPK1ALDH1A1GPR35

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107903217-B Preparation method of anagrelide impurity B 湖北省宏源药业科技股份有限公司 2021-11-23 — — CN claimed
CN-107903217-B Preparation method of anagrelide impurity B 湖北省宏源药业科技股份有限公司 2021-11-23 — — CN disclosed
EP-2630148-B1 PROCESS FOR THE PREPARATION OF ANAGRELIDE AND ANALOGUES THEREOF SHIRE LLC (US) 2020-11-25 — — EP disclosed
EP-1836202-B1 AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS ACADIA PHARM INC (US) 2016-12-21 — — EP disclosed
CN-103180323-B For the method preparing anagrelide and the like 夏尔有限责任公司 2016-08-10 — — CN disclosed
US-9067944-B2 Process for the preparation of anagrelide and analogues thereof SHIRE LLC (US) 2015-06-30 — — US disclosed
US-9067944-B2 Process for the preparation of anagrelide and analogues thereof SHIRE LLC (US) 2015-06-30 — — US disclosed
US-9067944-B2 Process for the preparation of anagrelide and analogues thereof SHIRE LLC (US) 2015-06-30 — — US disclosed
US-8530651-B2 Process for the preparation of anagrelide and analogues SHIRE LLC (US) 2013-09-10 — — US disclosed
US-8530651-B2 Process for the preparation of anagrelide and analogues SHIRE LLC (US) 2013-09-10 — — US disclosed
WO-2006076317-A2 AMINOPHENYL DERIVATIVES AS SELECTIVE ANDROGEN RECEPTOR MODULATORS ACADIA PHARMACEUTICALS INC. (US) 2006-07-20 — — WO disclosed
US-20060160845-A1 Aminophenyl derivatives as selective androgen receptor modulators ACADIA PHARMACEUTICALS INC. 2006-07-20 — — US disclosed
EP-1373268-A2 METHOD FOR THE MANUFACTURE OF ANAGRELIDE Shire US Inc. (US) 2004-01-02 — — EP disclosed
US-6653500-B2 Making ethyl N-(2,3-dichloro-6-nitrobenzyl)glycine from 2,3-dichlorobenzaldehyde, reducing the glycine compound using tin dichloride or a catalyst and cyclization of the corresponding iminoquinazoline compound SHIRE US INC. 2003-11-25 — — US disclosed
US-20030114673-A1 2-AMINO-5,6-DIHALO-3,4-DIHYDROQUINAZOLINES WITH BLOOD PLATELET REDUCING PROPERTIES SHIRE US INC. 2003-06-19 — — US disclosed
US-20030060630-A1 Method for the manufacture of Anagrelide SHIRE US INC. 2003-03-27 — — US disclosed
US-6388073-B1 NITRATION A 3,4-DICHLOROBENZALDEHYDE; REDUCING; CHLORINATION; ALKYLATION; BROMOCYANATION; CHLIZATION SHIRE US INC. 2002-05-14 — — US disclosed
WO-2002008228-A2 METHOD FOR THE MANUFACTURE OF ANAGRELIDE SHIRE US INC (US) 2002-01-31 — — WO disclosed
WO-2001040196-A1 2-AMINO-5,6-DIHALO-3,4-DIHYDROQUINAZOLINES WITH BLOOD PLATELET REDUCING PROPERTIES ROBERTS LABORATORIES INC. (US) 2001-06-07 — — WO disclosed
US-6194420-B1 BLOOD DISORDERS; REDUCE PLATELET CONCENTRATION ROBERTS LABORATORIES INC. 2001-02-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030114673-A1 2-AMINO-5,6-DIHALO-3,4-DIHYDROQUINAZOLINES WITH BLOOD PLATELET REDUCING PROPERTIES THPO, F2, PF4 TDP1 520/4885TSHR 3625/4885MAPK1 4558/4885
US-20030060630-A1 Method for the manufacture of Anagrelide SUCLG2, PDCD2L, ICOSLG TDP1 2354/4885TSHR 4065/4885MAPK1 3761/4885
US-20060160845-A1 Aminophenyl derivatives as selective androgen receptor modulators AR, NR5A1, ESRRA TDP1 2425/4885TSHR 424/4885MAPK1 1686/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.